PSPEN (Pakistan Society for Parenteral & Enteral Nutrition) officially in establishment phase – Founding initiative launchedCall for Applications: PSPEN Founding Executive Council – Applications Now OpenPSPEN invites healthcare professionals to join its leadership structure through voluntary rolesExecutive Council formation in progress – Selection based on professional merit and commitmentPSPEN aims to strengthen clinical nutrition, parenteral & enteral nutrition practices in PakistanFounding phase initiatives underway for education, research, and clinical collaboration frameworkOpportunity to contribute in national clinical nutrition society – PSPEN leadership engagement openPSPEN official membership structure and programs will be announced soonPSPEN (Pakistan Society for Parenteral & Enteral Nutrition) officially in establishment phase – Founding initiative launchedCall for Applications: PSPEN Founding Executive Council – Applications Now OpenPSPEN invites healthcare professionals to join its leadership structure through voluntary rolesExecutive Council formation in progress – Selection based on professional merit and commitmentPSPEN aims to strengthen clinical nutrition, parenteral & enteral nutrition practices in PakistanFounding phase initiatives underway for education, research, and clinical collaboration frameworkOpportunity to contribute in national clinical nutrition society – PSPEN leadership engagement openPSPEN official membership structure and programs will be announced soon
The Global Leadership Initiative on Malnutrition (GLIM) was launched in 2016 and published in 2019 by leading clinical nutrition societies worldwide to create one universal diagnostic approach for adult malnutrition, usable across all settings and regions — including South Asia / Pakistan.
Two-step workflow: (1) Screen for risk with validated tool → (2) Assess for diagnosis
Diagnosis requires: At least 1 phenotypic (weight loss / low BMI / low muscle mass) + 1 etiologic (reduced intake/assimilation OR inflammation/disease burden)
Severity grading: Based on severity of phenotypic criteria — Stage 1 Moderate and Stage 2 Severe
Muscle mass included as core criterion — acknowledges sarcopenia component
Endorsed by PSPEN for hospital and community practice in Pakistan with Asian BMI adaptation
2
Steps: Screen + Assess
5
Criteria: 3P + 2E
1+1
Required for Diagnosis
2
Severity Stages
2018
Consensus Year
Interactive Calculator
⚡ GLIM Diagnosis & Severity Calculator
Enter patient data — GLIM phenotypic, etiologic, diagnosis and severity stage are calculated automatically.
👆 Fill patient data — initial risk, phenotypic, etiologic, diagnosis and severity stage will appear here
📋 GLIM Clinical Flowchart — Two-Step Diagnostic Process
Diagnosis requires AT LEAST 1 phenotypic criterion + AT LEAST 1 etiologic criterion
🧬 Phenotypic Criteria (3) — Need ≥13 criteria
1
Non-volitional Weight LossWithin past 6 months: >5% · Beyond 6 months: >10% · Thresholds guide severity (see below)
2
Low Body Mass IndexGlobal: <20 kg/m² if <70y, <22 if ≥70y · Asia (incl. Pakistan): <18.5 if <70y, <20 if ≥70y for diagnosis; lower thresholds define severity
3
Reduced Muscle MassReduction confirmed by validated body composition (BIA, DXA, CT), anthropometry (calf/MUAC), or functional surrogate (handgrip as supportive)
🔥 Etiologic Criteria (2) — Need ≥12 criteria
A
Reduced Food Intake or Assimilation≤50% of energy requirements >1 week OR any reduction >2 weeks OR any chronic GI condition impairing assimilation/malabsorption (dysphagia, nausea, vomiting, diarrhea, obstruction)
Weight loss: >10% within past 6 months OR >20% beyond 6 months
BMI: Global: <18.5 if <70y, <20 if ≥70y · Asia: <17 if <70y, <17.5 if ≥70y (some use <17.5/<18)
Muscle mass: Severe deficit (marked loss on exam, imaging or anthropometry)
How to assign severity:If any phenotypic meets severe threshold → classify as Stage 2 Severe, even if other phenotypic are moderate. Otherwise if all phenotypic at least moderate → Stage 1 Moderate.
Clinical implication:Severity guides intensity of nutrition support, monitoring frequency, and need for specialist referral. Severe = higher priority for dietitian + EN/PN assessment.
⚠️ Important: GLIM diagnosis does not replace clinical judgement. Always assess functional status, comorbidities, and patient goals. Muscle mass may be difficult to measure — use calf circumference (<31 cm presumptive), MUAC, or validated clinical assessment if BIA/DXA/CT unavailable. Inflammation may be inferred from disease, fever, elevated CRP/procalcitonin, low albumin (not specific). Re-assess every 3–6 months or after clinical change.
★ PAKISTAN SOCIETY FOR PARENTERAL & ENTERAL NUTRITION ★
FFMI <17 M / <15 F kg/m² low; SMI cut-offs by device/population
Muscle: Anthropometry
Calf circumference (CC), mid-upper arm circumference (MUAC)
CC <31 cm = low; MUAC <23 cm undernutrition, <19 severe — rapid bedside
Muscle: Imaging
DXA, CT at L3
CT L3 SMI <52.4 M / <38.5 F cm²/m² = low (cancer); DXA appendicular SMI
Best Practice
💡 PSPEN — How to Implement GLIM in Pakistan
🏥 In Hospitals
1. Screen all admissions within 24h with NRS-2002 or MUST. 2. If at risk → perform GLIM assessment within 48h. 3. Document phenotypic + etiologic + severity stage in notes. 4. Refer Stage 1 to ward dietitian, Stage 2 to senior dietitian/nutrition team urgently.
Integration with EMR — Add GLIM checklist to admission form
📏 Muscle Mass Practical Tips
In low-resource setting, use calf circumference (best single anthropometric predictor) + subjective assessment of temporalis, interosseous, quadriceps wasting. Handgrip strength as supportive functional measure (<27kg M, <16kg F low).
Training nurses to measure CC correctly at maximum calf girth
Energy 25–30 kcal/kg, protein 1.0–1.5 g/kg (higher in severe / catabolic)
FAQ
❓ GLIM — Frequently Asked Questions
Q1. How is GLIM different from MUST or NRS-2002?
MUST/NRS-2002 = Screening tools to identify at-risk patients. GLIM = Diagnostic criteria to confirm malnutrition diagnosis and grade severity. GLIM Step 1 says you must first screen with a validated tool like MUST/NRS. So they are complementary — screen with MUST/NRS, then diagnose with GLIM.
Q2. Do I need to measure muscle mass to diagnose GLIM malnutrition?
Not necessarily. GLIM has 3 phenotypic criteria — you need only 1 of them. If patient has clear weight loss >5% or low BMI, you can diagnose without muscle mass measurement. Muscle mass adds sensitivity, especially when weight loss/BMI are not obvious (e.g., edema, obesity). If BIA/DXA unavailable, use calf circumference or clinical assessment of muscle wasting.
Q3. What Asian BMI thresholds should I use for Pakistan?
GLIM original global thresholds are <20 (<70y) and <22 (≥70y) for moderate, <18.5 and <20 for severe. For Asian populations including Pakistan, GLIM suggests lower thresholds may be appropriate: many Pakistani studies use <18.5 (<70y) and <20 (≥70y) as moderate, and <17 (<70y) and <17.5 (≥70y) as severe. Our calculator notes Asian option — use clinical judgement and local validation.
Q4. If patient has 2 phenotypic criteria (one moderate, one severe) — what severity stage?
GLIM severity is determined by the most severe phenotypic indicator. If any phenotypic meets severe threshold, classify as Stage 2 Severe malnutrition, even if other phenotypic are only moderate. Document all phenotypic present.
Q5. Patient is obese but has weight loss and low muscle mass — can they be malnourished by GLIM?
Yes. This is sarcopenic obesity. An obese patient (BMI >30) with weight loss >10%, reduced muscle mass and inflammation/reduced intake can be diagnosed as malnourished by GLIM. Do not exclude obese patients — assess muscle mass and weight loss.
Q6. Is low albumin an etiologic criterion?
No. GLIM explicitly states albumin is NOT a nutritional marker but reflects inflammation. Hypoalbuminemia can be supportive of inflammation but is not itself a diagnostic criterion. Use CRP, clinical disease burden, and intake data instead.
Q7. How often should I re-assess GLIM?
Initial GLIM diagnosis at admission if at risk. Re-assess every 3–6 months in community, weekly during acute hospitalization, or whenever clinical condition changes significantly (surgery, infection, deterioration).